Posted by Administrator on January 11th, 2006 — in Allegra Top News
BRIDGEWATER, N.J., Sept. 12 — Sanofi-aventis announced today that its subsidiary Aventis Pharmaceuticals Inc. has signed a distribution and supply agreement with Prasco Laboratories to launch an authorized generic fexofenadine hydrochloride tablet in the United States. This generic product will be distributed in 30 mg, 60 mg and 180 mg formulations. Financial terms of the […]
No Comments »
Posted by Administrator on January 11th, 2006 — in Allegra Top News
Once-daily formulation provides 24-hour relief of seasonal allergy symptoms with nasal congestion
Jul 27, 2005
BRIDGEWATER, N.J., July 27 — Sanofi-aventis announced today that Allegra-D(R) 24 Hour (fexofenadine HCl 180 mg/pseudophedrine HCl 240 mg) Extended-Release Tablets are now available for the treatment of seasonal allergy symptoms with nasal congestion in adults and children 12 years of age […]
No Comments »
Posted by Administrator on January 11th, 2006 — in Allegra Top News
WOODCLIFF LAKE, N.J., Sept. 1 — Barr Pharmaceuticals, Inc. ( NYSE = BRL ) today announced that Barr Laboratories, Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its generic versions of Aventis Pharmaceuticals’ Allegra(R) (Fexofenadine Hydrochloride) Tablets, 30 mg, 60 mg and 180 mg. The Company believes it is […]
No Comments »